Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC): Protocol for a Randomized Controlled Trial Investigating Effects on Clinical Outcomes, Adherence, and Quality of Life

Malin Johansson Östbring, Tommy Eriksson, Göran Petersson, Lina Hellström, Malin Johansson Östbring, Tommy Eriksson, Göran Petersson, Lina Hellström

Abstract

Background: Preventive treatment goals for blood pressure and cholesterol levels continue to be unmet for many coronary patients. The effect of drug treatment depends on both its appropriateness and the patients' adherence to the treatment regimen. There is a need for adherence interventions that have a measurable effect on clinical outcomes.

Objective: This study aims to evaluate the effects on treatment goals of an intervention designed to improve patient adherence and treatment quality in secondary prevention of coronary heart disease. A protocol for the prespecified process evaluation of the trial is published separately.

Methods: The Motivational Interviewing and Medication Review in Coronary heart disease (MIMeRiC) trial is a prospective, randomized, outcomes-blinded trial designed to compare individualized follow-up by a clinical pharmacist using motivational interviewing (MI) and medication review with standard follow-up. Patients were randomized to 2 groups after stratification according to their beliefs about medicines. After standard follow-up at the cardiology clinic, patients in the intervention group are seen individually by a clinical pharmacist 2 to 5 times as required over 7 months, at the clinic. The pharmacist reviews each patient's medication and uses MI to manage any problems with prescribing and adherence. The primary study outcome is the proportion of patients who have reached the treatment goal for low-density lipoprotein cholesterol by 12 months after discharge. Secondary outcomes are the effects on patient adherence, systolic blood pressure, disease-specific quality of life, and health care use.

Results: The protocol for this study was approved by the Regional Ethics Committee, Linköping, in 2013. Enrollment started in October 2013 and ended in December 2016 when 417 patients had been included. Follow-up data collection will conclude in March 2018. Publication of the primary and secondary outcome results from the MIMeRiC trial is anticipated in 2019.

Conclusions: The MIMeRiC trial will assess the effectiveness of an intervention involving medication reviews and individualized support. The results will inform the continued development of support for this large group of patients who use preventive medicines for lifelong treatment. The design of this adherence intervention is based on a theoretical framework and is the first trial of an intervention that uses beliefs about medicines to individualize the intervention protocol.

Trial registration: ClinicalTrials.gov NCT02102503; https://ichgcp.net/clinical-trials-registry/NCT02102503 (Archived by WebCite at http://www.webcitation.org/6x7iUDohy).

Keywords: coronary artery disease; medication adherence; medication therapy management; pharmacist; randomized controlled trial.

Conflict of interest statement

Conflicts of Interest: None declared.

©Malin Johansson Östbring, Tommy Eriksson, Göran Petersson, Lina Hellström. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 20.02.2018.

Figures

Figure 1
Figure 1
Study flow chart. Each box represents a separate event. White boxes are standard care events, light gray boxes are study events; BMQ-S: Beliefs about Medicines Questionnaire-Specific; BP: blood pressure; LDL-C: low density lipoprotein cholesterol; QoL: quality of life.
Figure 2
Figure 2
Flow diagram of study participants, status as of April 2017. For those excluded, (i) indicates cognitive impairment or any other condition making interviews or phone calls difficult; (ii) indicates nonparticipation in the standard follow-up at the out-patient clinic; and (iii) indicates prior participation in this study. LDL-C: low-density lipoprotein cholesterol; BP: blood pressure.

References

    1. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi M, Mensah GA, Murray CJL. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015 Apr 02;372(14):1333–41. doi: 10.1056/NEJMoa1406656.
    1. Bhatnagar P, Wickramasinghe K, Wilkins E, Townsend N. Trends in the epidemiology of cardiovascular disease in the UK. Heart. 2016 Dec 15;102(24):1945–1952. doi: 10.1136/heartjnl-2016-309573.
    1. Socialstyrelsen. Official statistics of Sweden; 2015. [2018-02-06]. Myocardial Infarctions in Sweden 1994-2014 .
    1. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008 Apr;155(4):772–9. doi: 10.1016/j.ahj.2007.12.011.
    1. Kotseva K, De Bacquer D, Jennings C, Gyberg V, De Backer G, Rydén L, Amouyel P, Bruthans J, Cifkova R, Deckers JW, De Sutter J, Fraz Z, Graham I, Keber I, Lehto S, Moore D, Pajak A, Wood D, EUROASPIRE Investigators Time trends in lifestyle, risk factor control, and use of evidence-based medications in patients with coronary heart disease in Europe: results from 3 EUROASPIRE surveys, 1999-2013. Glob Heart. 2017 Dec;12(4):315–322.e3. doi: 10.1016/j.gheart.2015.11.003.
    1. Libungan B, Stensdotter L, Hjalmarson A, From Attebring M, Lindqvist J, Bäck M, Herlitz J. Secondary prevention in coronary artery disease. Achieved goals and possibilities for improvements. Int J Cardiol. 2012 Nov 01;161(1):18–24. doi: 10.1016/j.ijcard.2011.04.025.
    1. Hambraeus K, Lindhagen L, Tydén P, Lindahl B, Lagerqvist B. Target-attainment rates of low-density lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in sweden. Am J Cardiol. 2014 Jan 01;113(1):17–22. doi: 10.1016/j.amjcard.2013.09.007.
    1. Kramer JM, Hammill B, Anstrom KJ, Fetterolf D, Snyder R, Charde JP, Hoffman BS, Allen LN, Peterson E. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006 Sep;152(3):454.e1–8. doi: 10.1016/j.ahj.2006.02.030.
    1. World Health Organization. Geneva: 2003. [2018-02-06]. Adherence to long-term therapies - evidence for action .
    1. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011. doi: 10.1002/14651858.CD000011.pub3.
    1. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, Agoritsas T, Mistry N, Iorio A, Jack S, Sivaramalingam B, Iserman E, Mustafa RA, Jedraszewski D, Cotoi C, Haynes RB. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011. doi: 10.1002/14651858.CD000011.pub4.
    1. Conn VS, Ruppar TM. Medication adherence outcomes of 771 intervention trials: systematic review and meta-analysis. Prev Med. 2017 Jun;99:269–276. doi: 10.1016/j.ypmed.2017.03.008.
    1. van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R. Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev. 2016 Dec 21;12:CD004371. doi: 10.1002/14651858.CD004371.pub4.
    1. Santo K, Kirkendall S, Laba TL, Thakkar J, Webster R, Chalmers J, Chow CK, Redfern J. Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials. Eur J Prev Cardiol. 2016 Jul;23(10):1065–76. doi: 10.1177/2047487316638501.
    1. Dunn SP, Birtcher KK, Beavers CJ, Baker WL, Brouse SD, Page 2nd RL, Bittner V, Walsh MN. The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol. 2015 Nov 10;66(19):2129–2139. doi: 10.1016/j.jacc.2015.09.025.
    1. Clark C, Smith L, Cloutier L, Glynn L, Clark O, Taylor R, Campbell J. LB01.01: Allied health professional-led interventions for improving control of blood pressure in patients with hypertension: a Cochrane systematic review and meta-analysis. J Hypertens. 2015 Jun;33 Suppl 1:e44. doi: 10.1097/01.hjh.0000467463.16386.51.
    1. Santschi V, Chiolero A, Colosimo AL, Platt RW, Taffé P, Burnier M, Burnand B, Paradis G. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014 Apr 10;3(2):e000718. doi: 10.1161/JAHA.113.000718.
    1. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011 Sep 12;171(16):1441–53. doi: 10.1001/archinternmed.2011.399.
    1. Zomahoun HT, Guénette L, Grégoire JP, Lauzier S, Lawani AM, Ferdynus C, Huiart L, Moisan J. Effectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysis. Int J Epidemiol. 2017 Apr 01;46(2):589–602. doi: 10.1093/ije/dyw273.
    1. Palacio A, Garay D, Langer B, Taylor J, Wood BA, Tamariz L. Motivational interviewing improves medication adherence: a systematic review and meta-analysis. J Gen Intern Med. 2016 Aug;31(8):929–40. doi: 10.1007/s11606-016-3685-3.
    1. Easthall C, Song F, Bhattacharya D. A meta-analysis of cognitive-based behaviour change techniques as interventions to improve medication adherence. Br Med J Open. 2013 Aug 09;3(8) doi: 10.1136/bmjopen-2013-002749.
    1. Al-Ganmi AH, Perry L, Gholizadeh L, Alotaibi AM. Cardiovascular medication adherence among patients with cardiac disease: a systematic review. J Adv Nurs. 2016 Dec;72(12):3001–3014. doi: 10.1111/jan.13062.
    1. Östbring MJ, Eriksson T, Petersson G, Hellström L. Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC): intervention development and protocol for the process evaluation. JMIR Res Protoc. 2018 Jan 30;7(1):e21. doi: 10.2196/resprot.8660.
    1. Horne R, Chapman SC, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013;8(12):e80633. doi: 10.1371/journal.pone.0080633.
    1. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999 Dec;47(6):555–67.
    1. Horne R, Parham R, Driscoll R, Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009 Jun;15(6):837–44. doi: 10.1002/ibd.20846.
    1. Tibaldi G, Clatworthy J, Torchio E, Argentero P, Munizza C, Horne R. The utility of the Necessity--Concerns Framework in explaining treatment non-adherence in four chronic illness groups in Italy. Chronic Illn. 2009 Jun;5(2):129–33. doi: 10.1177/1742395309102888.
    1. Pharmaceutical Care Network Europe. 2016. [2018-02-06]. Position Paper on the PCNE definition of Medication Review 2016 .
    1. Hellström LM, Bondesson A, Höglund P, Midlöv P, Holmdahl L, Rickhag E, Eriksson T. Impact of the Lund Integrated Medicines Management (LIMM) model on medication appropriateness and drug-related hospital revisits. Eur J Clin Pharmacol. 2011 Jul;67(7):741–52. doi: 10.1007/s00228-010-0982-3.
    1. Hellström LM, Höglund P, Bondesson A, Petersson G, Eriksson T. Clinical implementation of systematic medication reconciliation and review as part of the Lund Integrated Medicines Management model--impact on all-cause emergency department revisits. J Clin Pharm Ther. 2012 Dec;37(6):686–92. doi: 10.1111/jcpt.12001.
    1. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208.
    1. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011 Dec;20(10):1727–36. doi: 10.1007/s11136-011-9903-x.
    1. SWEDEHEART Working group Uppsala Clinical Research Center. 2013. SWEDEHEART Annual Report 2012 .
    1. Socialstyrelsen. [2018-02-06]. Öppna jämförelser av hälso- och sjukvårdens kvalitet och effektivitet. Jämförelser mellan landsting 2012 .
    1. SWEDEHEART Working group Uppsala Clinical Research Center. 2016. SWEDEHEART Annual Report 2015 .
    1. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012 May;73(5):691–705. doi: 10.1111/j.1365-2125.2012.04167.x.
    1. Krousel-Wood M, Holt E, Joyce C, Ruiz R, Dornelles A, Webber LS, Morisky DE, Frohlich ED, Re RN, He J, Whelton PK, Muntner P. Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the Cohort Study of Medication Adherence among Older Adults (CoSMO) J Hypertens. 2015 Feb;33(2):412–20. doi: 10.1097/HJH.0000000000000382.
    1. Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol. 2011 Mar;64(3):255–7; discussion 258. doi: 10.1016/j.jclinepi.2010.09.002.
    1. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008 May;10(5):348–54.
    1. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009 Jan;15(1):59–66.
    1. Natarajan N, Putnam RW, Yip AM, Frail D. Family practice patients' adherence to statin medications. Can Fam Physician. 2007 Dec;53(12):2144–5.
    1. Bermingham M, Hayden J, Dawkins I, Miwa S, Gibson D, McDonald K, Ledwidge M. Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. Clin Ther. 2011 Sep;33(9):1180–9. doi: 10.1016/j.clinthera.2011.07.007.
    1. Glader EL, Sjölander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010 Feb;41(2):397–401. doi: 10.1161/STROKEAHA.109.566950.
    1. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014 Oct;78(4):684–98.
    1. Oldridge N, Höfer S, McGee H, Conroy R, Doyle F, Saner H, (for the HeartQoL Project Investigators) The HeartQoL: part II. Validation of a new core health-related quality of life questionnaire for patients with ischemic heart disease. Eur J Prev Cardiol. 2014 Jan;21(1):98–106. doi: 10.1177/2047487312450545.
    1. Conn VS, Ruppar TM, Enriquez M, Cooper PS. Patient-centered outcomes of medication adherence interventions: systematic review and meta-analysis. Value Health. 2016;19(2):277–85. doi: 10.1016/j.jval.2015.12.001.
    1. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005 May 01;21(6):485–8.
    1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PW, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 01;63(25 Pt B):2889–934. doi: 10.1016/j.jacc.2013.11.002.
    1. Matthews A, Herrett E, Gasparrini A, Van Staa T, Goldacre B, Smeeth L, Bhaskaran K. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. Br Med J. 2016 Jun 28;353:i3283.
    1. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016 Mar 14;37(11):908–916. doi: 10.1093/eurheartj/ehv641.
    1. Hakkarainen KM, Andersson Sundell K, Petzold M, Hägg S. Prevalence and perceived preventability of self-reported adverse drug events--a population-based survey of 7099 adults. PLoS One. 2013;8(9):e73166. doi: 10.1371/journal.pone.0073166.
    1. Krska J, Morecroft CW, Poole H, Rowe PH. Issues potentially affecting quality of life arising from long-term medicines use: a qualitative study. Int J Clin Pharm. 2013 Dec;35(6):1161–9. doi: 10.1007/s11096-013-9841-5.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner